All In MedTech

Device Trial Radar · NCT02659098

A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy

A Phase 2b, Multicenter, Double-masked, Randomized Study Evaluating the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy Secondary to Age Related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

21

Actual

Start

Dec 4, 2015

Primary completion

Jun 5, 2019

Study completion Jun 5, 2019

Sponsor

Lead sponsor
Janssen Research & Development, LLCNot on our public-company list
Sponsor type
Industry
First posted
Jan 20, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 55 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and performance profile of the suprachoroidal surgical approach and the Delivery System.

Conditions

  • Visual Acuity
  • Geographic Atrophy
  • Macular Degeneration

Interventions

  • CNTO 2476 3.0 x 10^5 cellsDrug

    Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10\^5 cells in 50 microliter (mcL) given by subretinal Delivery System.

  • Subretinal Delivery SystemDevice

    Participants will receive CNTO 2476 by using the Delivery System.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) Total Letters Score at Month 1- Treated EyeTime frame: Baseline and Month 1
  2. Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 2- Treated EyeTime frame: Baseline and Month 2
  3. Change From Baseline in Best Corrected Visual Acuity Total Letters Score at Month 3- Treated EyeTime frame: Baseline and Month 3

15 more outcomes with a free account

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Arcadia, California

  • Site not named

    Chicago, Illinois

  • Site not named

    Lexington, Kentucky

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.